Workshop outcomes report: Initiatives to establish a European Network of pharmacogenetics/genomics and progress

European Journal of Pharmaceutical Sciences

Volumn 31, Issue 3-4, 2007, Pages 151-155

  Maitland van der Zee, Anke Hilse ^a   Aitchison, Katherine ^b   Kirchheiner, Julia ^c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

European Network; Pharmacogenetics; Pharmacogenomics; Workshop

Indexed keywords

ARTICLE; DRUG INDUSTRY; EUROPE; GENETIC POLYMORPHISM; GENOTYPE; OUTCOMES RESEARCH; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 34249979030     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2007.03.009     Document Type: Note

References (6)

1. Brosen K. Some aspects of genetic polymorphism in the biotransformation of anti-depressants. Therapie 59 1 (2004) 5-12
2. Kirchheiner J., and Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77 1 (2005) 1-16
3. Maitland-van der Zee A.H., and Boerwinkle E. Pharmacogenetics of response to statins: where do we stand?. Curr. Atheroscler. Rep. 7 3 (2005) 204-208
4. Mirghani R.A., et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genom. 16 9 (2006) 637-645
5. Rodin A., et al. Mining genetic epidemiology data with Bayesian Networks application to APOE gene variation and plasma lipid levels. J. Comput. Biol. 12 1 (2005) 1-11
6. Sadee W. Pharmacogenomics. BMJ 319 7220 (1999) 1286